Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Kyverna Therapeutics, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
KYTX
Nasdaq
2830
kyvernatx.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Kyverna Therapeutics, Inc.
Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer
- Jan 21st, 2025 9:05 pm
Here's Why We're Watching Kyverna Therapeutics' (NASDAQ:KYTX) Cash Burn Situation
- Jan 15th, 2025 12:19 pm
Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
- Jan 13th, 2025 12:30 pm
Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors
- Jan 8th, 2025 1:00 pm
Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference
- Jan 6th, 2025 9:05 pm
Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth
- Dec 13th, 2024 9:05 pm
institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop
- Nov 17th, 2024 1:14 pm
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
- Nov 14th, 2024 3:01 pm
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
- Nov 13th, 2024 9:14 pm
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
- Oct 21st, 2024 12:00 pm
Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy
- Oct 19th, 2024 3:13 pm
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc
- Oct 10th, 2024 7:05 pm
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
- Sep 18th, 2024 12:00 pm
Kyverna Therapeutics Announces Leadership Update
- Sep 16th, 2024 12:00 pm
Kyverna swaps CEOs, leaning on Kite veterans to lead ‘next chapter’
- Sep 16th, 2024 10:58 am
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
- Aug 21st, 2024 8:05 pm
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
- Aug 12th, 2024 8:08 pm
Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis
- Aug 12th, 2024 8:05 pm
We Think Kyverna Therapeutics (NASDAQ:KYTX) Can Afford To Drive Business Growth
- Aug 8th, 2024 10:44 am
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
- Jul 18th, 2024 1:38 pm
Scroll